the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Rizab antarabangsa BNM berjumlah US$113.4b pada 15 Mac 2024

KUALA LUMPUR: Rizab antarabangsa Bank Negara Malaysia (BNM) berjumlah US$113.4 bilion (US$1=RM4.731) pada 15 Mac 2024 berbanding dengan US$114.3 bilion pada 29 Feb 2024.

Menurut bank pusat, paras rizab itu memadai untuk membiayai 5.4 bulan import barangan dan perkhidmatan dan 1.0 kali jumlah hutang luar negeri jangka pendek.

Komponen utama rizab antarabangsa meliputi rizab mata wang asing berjumlah US$100.8 bilion, diikuti kedudukan rizab Tabung Kewangan Antarabangsa (US$1.4 bilion), hak pengeluaran khas (SDR) (US$5.8 bilion), emas (US$2.6 bilion) dan aset rizab lain (US$2.8 bilion).

Jumlah aset sebanyak RM620.64 bilion merangkumi emas dan pertukaran asing dan rizab lain, termasuk SDR (RM520.34 bilion), kertas kerajaan Malaysia (RM13.0 bilion), deposit dengan institusi kewangan (RM2.44 bilion), pinjaman dan pendahuluan (RM24.55 bilion), tanah dan bangunan (RM4.13 bilion) dan aset-aset lain (RM56.19 bilion).

BNM berkata modal dan liabiliti terdiri daripada modal berbayar (RM100 juta), rizab (RM189.39 bilion), mata wang dalam edaran (RM168.01 bilion), deposit oleh institusi kewangan (RM150.93 bilion), deposit kerajaan persekutuan (RM9.05 bilion), deposit lain (RM39.89 bilion), kertas Bank Negara (RM29.80 bilion), peruntukan SDR (RM29.74 bilion) dan liabiliti-liabiliti lain (RM3.73 bilion). –Bernama

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Addressing medical inflation

Consumers are struggling as medical insurance premiums surge, with over 340,000 dropping coverage amid calls for price regulation and stronger public healthcare

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings